Xuanfei Baidu Granules for COVID-19

A number of treatments are available for Covid-19, however, they were poorly communicated or inconsistent in their use. Further collaborative research would help with these issues. Copyright © 2020 The Authors. Urologic Oncology, published by Wiley Periodicals, Inc. on behalf of International Commission on Urological Oncology.

Patients with cough must be tested for respiratory illness in an emergency department. A history is an important part of the assessment process for patients with cough to assess for other causes of cough and a diagnosis can facilitate implementation of appropriate patient management. The cough should be quantitatively assessed for number of days of cough and other cough symptoms for cough severity and the number of days of fever.

We found no evidence that this disease can be cured, only that it can be controlled, as most people do not make any long-term clinical or virologic deterioration.

In the United States, the number of reported infected cases has been relatively consistent. As of May 23, 2019, 11,946 confirmed cases had been reported in the United States (0.16% of all reported cases), which is 1,744 cases less than the peak reported as of May 3, New York City has reported more cases than any other city or state. Many individuals who have developed symptoms or had exposure to an individual who developed symptoms or had exposure to any of the 9 states in the Northeast or Southeast have been hospitalized with symptoms consistent with covid-19, including cases reported as far east as the Carolinas. Since the virus can remain infectious for months or years, additional cases may go unreported.

It is estimated that the age-adjusted ratio of disease to death is 7.7 and the ratio of deaths to morbidity is 0.7. Results from a recent clinical trial underscore that, over time, new virus variants are continually arising and are adapted to and transmitted among hosts. They also shed light on the importance of health systems in protecting the community from potential health care disasters.

Covid-19, commonly known as coronavirus disease 2019, has killed close to 2,500 people and caused hundreds more to be sick worldwide as of January 2020. It was declared as a national security concerns by the WHO in Wuhan, China which has since become infected. In the outbreak, over 70% of patients were reported as recovered in China, despite no treatment. This is likely because of a significant proportion of patients having been misdiagnosed as simple pneumonia which is treatable without antivirus drug. Hence, the majority of those with actual infection with the virus don't know their cure.

XFBG is generally well-tolerated in clinical practice. However, the most frequent adverse effects were headache (11.6%), and constipation (10.2%). In contrast, the most common side effects of yanzhuang tablets were dizziness (23.4%), fatigue (14% of patients), insomnia (13.8%), headache (13.1%), nausea (11.5%), diarrhea (10.1%), and dyspepsia (1.6%).

There is not always good evidence of clinical syndromes related to current coronaviruses. It seems that for some, the disease may be less severe. At the same time, even these mild and sub-clinical symptoms may be of concern to families and hospitals as the number of cases increases.

Xinxue baidu granules may not shorten the course of, or otherwise improve the quality of life of patients with a confirmed diagnosis of covid-19. These data highlight the need for ongoing trials of treatment alternatives and new and better-designed trials for patients with covid-19.

XGBJX has been used in clinical practice for a long time. The studies related to xuanfei baidu granule were limited and did not show much evidence. A study with a larger patient sample was urgently needed.

The following should be considered by clinicians when evaluating a new treatment for COVID-19: \n- Identifying if COVID-19 has been studied before to determine potential side-effects;\n- Identifying prior treatments that may be useful in limiting the side effects of a particular treatment; and\n- Identifying any comorbidities that may increase the risk of serious complications.\nUsing these factors will help guide clinicians when considering potential clinical trials. [Power.net®] and [PubHealth®] help patients find clinical trials tailored to their conditions, location, and optimal treatments.